Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
US Department of Justice
Cantor Fitzgerald
Teva
Covington
Mallinckrodt
Queensland Health
Johnson and Johnson
Chinese Patent Office

Generated: June 20, 2018

DrugPatentWatch Database Preview

Smithkline Beecham Company Profile

« Back to Dashboard

What is the competitive landscape for SMITHKLINE BEECHAM, and when can generic versions of SMITHKLINE BEECHAM drugs launch?

SMITHKLINE BEECHAM has six approved drugs.

There are two US patents protecting SMITHKLINE BEECHAM drugs.

There are fifty patent family members on SMITHKLINE BEECHAM drugs in sixteen countries.

Summary for Smithkline Beecham
International Patents:50
US Patents:2
Tradenames:6
Ingredients:6
NDAs:6
Drug Master File Entries: 2
Patent Litigation for Smithkline Beecham: See patent lawsuits for Smithkline Beecham

Drugs and US Patents for Smithkline Beecham

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Smithkline Beecham COREG CR carvedilol phosphate CAPSULE, EXTENDED RELEASE;ORAL 022012-003 Oct 20, 2006 AB RX Yes Yes 7,268,156*PED ➤ Try a Free Trial Y ➤ Try a Free Trial
Smithkline Beecham AXID nizatidine CAPSULE;ORAL 019508-001 Apr 12, 1988 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Smithkline Beecham COREG CR carvedilol phosphate CAPSULE, EXTENDED RELEASE;ORAL 022012-002 Oct 20, 2006 AB RX Yes No 8,101,209*PED ➤ Try a Free Trial Y ➤ Try a Free Trial
Smithkline Beecham COREG carvedilol TABLET;ORAL 020297-002 Sep 14, 1995 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Smithkline Beecham

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Smithkline Beecham COREG CR carvedilol phosphate CAPSULE, EXTENDED RELEASE;ORAL 022012-001 Oct 20, 2006 6,022,562*PED ➤ Try a Free Trial
Smithkline Beecham DYNACIRC isradipine CAPSULE;ORAL 019546-002 Dec 20, 1990 4,466,972 ➤ Try a Free Trial
Smithkline Beecham COREG carvedilol TABLET;ORAL 020297-003 Sep 14, 1995 4,503,067*PED ➤ Try a Free Trial
Smithkline Beecham COREG carvedilol TABLET;ORAL 020297-003 Sep 14, 1995 5,902,821*PED ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for SMITHKLINE BEECHAM drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Capsules 10 mg and 20 mg ➤ Subscribe 2008-03-18
➤ Subscribe Extended-release Capsules 80 mg ➤ Subscribe 2007-11-19
➤ Subscribe Capsules 1 g ➤ Subscribe 2008-11-10
➤ Subscribe Extended-release Capsules 40 mg ➤ Subscribe 2007-12-21
➤ Subscribe Oral Solution 15 mg/mL ➤ Subscribe 2008-05-14

Non-Orange Book US Patents for Smithkline Beecham

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,902,378 Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment ➤ Try a Free Trial
7,626,041 Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment ➤ Try a Free Trial
7,893,100 Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment ➤ Try a Free Trial
7,759,384 Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Farmers Insurance
Deloitte
Julphar
McKesson
Merck
Baxter
Healthtrust
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.